Screener
Summit Therapeutics SMMT Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Summit Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026. Open the filing →
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
FAQ
- What is Summit Therapeutics's return on equity?
- Summit Therapeutics (SMMT) reported return on equity of -271% in Q1 2026.
- How has Summit Therapeutics's return on equity changed year-over-year?
- Summit Therapeutics's return on equity decreased by 118.6% year-over-year, from -123.9% to -271%.
- What is the long-term trend for Summit Therapeutics's return on equity?
- Over 5 years (2020 to 2025), Summit Therapeutics's return on equity has grown at a 25.4% compound annual growth rate (CAGR), from -66.6% to -206.1%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Summit Therapeutics's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude